Efficacy and tolerability of perospirone in schizophrenia: A systematic review and meta-analysis of randomized controlled trials

CNS Drugs

Volumn 27, Issue 9, 2013, Pages 731-741

  Kishi, Taro ^a   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CLOSPIPRAMINE; HALOPERIDOL; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE;

AKATHISIA; ANOREXIA; ANXIETY DISORDER; BRADYCARDIA; CLINICAL EFFECTIVENESS; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG INDUSTRY; DRUG TOLERABILITY; DYSKINESIA; DYSPHAGIA; DYSTONIA; DYSURIA; EJACULATION DISORDER; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEVER; GAIT DISORDER; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPERTENSION; HYPOTENSION; INCREASED APPETITE; INSOMNIA; LOSS OF APPETITE; META ANALYSIS; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SKIN DISEASE; SLEEP DISORDER; SOMNOLENCE; SPEECH DISORDER; SYSTEMATIC REVIEW; THORAX PAIN; TREMOR; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; THIAZOLES; YOUNG ADULT;

EID: 84883255857     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0085-7     Document Type: Review

References (20)

1. Onrust S, McClellan K. Perospirone. CNS Drugs. 2001;15(4):329-37.
2. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79-104.
3. Kishi T, Matsuda Y, Nakamura H, Iwata N. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res. 2013;47:149-54.
4. Takekita Y, Kato M, Wakeno M, Sakai S, Suwa A, Nishida K, et al. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013;40:110-4.
5. Kudo Y, Nakajima T, Saito M, Sakai T, Otsuki S, Yamasaki S, et al. Clinical evaluation of a serotonin-2 and dopamine-2 receptor antagonist (SDA), perospirone HCI on schizophrenia: a comparative double-blind study with mosapramine HCI. Clin Eval. 1997;24:207-48.
6. Murasaki M, Koyama T, Yukiteru M, Gohei Y, Kamijima K, Toru M, et al. Clinical evaluation of a new antipsychotic, perospirone HCI, on schizophrenia: a comparative double-blind study with haloperidol. Clin Eval. 1997;24:159-205.
7. Yamashita H, Mori K, Nagao M, Okamoto Y, Morinobu S, Yamawaki S. Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. J Clin Psychiatry. 2004;65:1525-30.
8. Okugawa G, Kato M, Wakeno M, Koh J, Morikawa M, Matsumoto N, et al. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci. 2009;63:322-8.
9. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76.
10. Cohn LD, Becker BJ. How meta-analysis increases statistical power. Psychol Methods. 2003;8(3):243-53.
11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-12.
12. Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res. 2002;57(2-3):227-38.
13. Inada T, Yagi G. Current topics in neuroleptic-induced extrapyramidal symptoms in Japan. Keio J Med. 1996;45(2):95-9.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
16. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
17. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-63.
18. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2012;38(1):167-77.
19. Inagaki A, Inada T. Equivalent doses of psychotropic drugs. Jpn J Clin Psychopharmacol. 2006;9(7):1443-7.
20. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-73.